{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:29:00Z","timestamp":1793302140507,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.kint.2023.09.027","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T19:00:01Z","timestamp":1698778801000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy"],"prefix":"10.1016","volume":"105","author":[{"given":"Hong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana V.","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-4811","authenticated-orcid":false,"given":"Hern\u00e1n","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitrij","family":"Kollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olympia","family":"Papachristofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Milojevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanna Kumar","family":"Nidamarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Charney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.09.027_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.09.027_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.09.027_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.kint.2023.09.027_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00281-021-00884-7","article-title":"Is IgA nephropathy the same disease in different parts of the world?","volume":"43","author":"Zhang","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kint.2023.09.027_bib6","first-page":"2493","article-title":"An update on the current state of management and clinical trials for IgA nephropathy","volume":"10","author":"Cheung","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2023.09.027_bib7","article-title":"Predicting progression of IgA nephropathy: new clinical progression risk score","volume":"7","author":"Xie","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.09.027_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.09.027_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ekir.2021.11.012","article-title":"Three-year clinical outcomes of the first South Asian prospective longitudinal observational IgA nephropathy cohort","volume":"7","author":"Alexander","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.09.027_bib10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.kint.2023.09.027_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib12","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.09.027_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.09.027_bib14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.09.027_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","article-title":"SGLT-2 inhibition in IgA nephropathy: the new standard of care?","volume":"100","author":"Barratt","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib17","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.09.027_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.09.027_bib19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.09.027_bib20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.09.027_bib21","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1001\/jama.2022.4638","article-title":"Oral glucocorticoids for IgA nephropathy","volume":"327","author":"Campbell","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2023.09.027_bib22","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib23","author":"Calliditas Therapeutics"},{"key":"10.1016\/j.kint.2023.09.027_bib24","author":"Stada Arzenimittel"},{"key":"10.1016\/j.kint.2023.09.027_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.ackd.2019.12.004","article-title":"Complement in IgA nephropathy: the role of complement in the pathogenesis, diagnosis, and future management of IgA nephropathy","volume":"27","author":"Medjeral-Thomas","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2023.09.027_bib27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.09.027_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jcla.20154","article-title":"Hypercomplementemia in adult patients with IgA nephropathy","volume":"21","author":"Onda","year":"2007","journal-title":"J\u00a0Clin Lab Anal"},{"key":"10.1016\/j.kint.2023.09.027_bib29","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.kint.2017.03.043","article-title":"Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy","volume":"92","author":"Medjeral-Thomas","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s11255-021-02997-2","article-title":"Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy","volume":"54","author":"Ji","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.kint.2023.09.027_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2023.09.027_bib32","first-page":"4715","article-title":"The contribution of complement to the pathogenesis of IgA nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases?","volume":"10","author":"Poppelaars","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2023.09.027_bib33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I\u2014molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.09.027_bib34","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.09.027_bib35","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.09.027_bib36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","article-title":"Combining multiple comparisons and modeling techniques in dose-response studies","volume":"61","author":"Bretz","year":"2005","journal-title":"Biometrics"},{"key":"10.1016\/j.kint.2023.09.027_bib37","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/sim.6052","article-title":"Model-based dose finding under model uncertainty using general parametric models","volume":"33","author":"Pinheiro","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2023.09.027_bib38","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.09.027_bib39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.09.027_bib40","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.09.027_bib41","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2023.09.027_bib42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.09.027_bib43","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"suppl 3","key":"10.1016\/j.kint.2023.09.027_bib44","article-title":"MO042 LNP023: a novel oral complement alternative pathway factor B inhibitor for the treatment of glomerular disease","volume":"35","author":"Webb","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.09.027_bib45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1471-2369-12-64","article-title":"Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function","volume":"12","author":"Onda","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2023.09.027_bib46","first-page":"820","article-title":"Urinary C5b-9 as a prognostic marker in IgA nephropathy","volume":"11","author":"Yu","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.kint.2023.09.027_bib47","first-page":"455","article-title":"Complement and bacterial infections: from molecular mechanisms to therapeutic applications","volume":"10","author":"Heesterbeek","year":"2018","journal-title":"J\u00a0Innate Immun"},{"key":"10.1016\/j.kint.2023.09.027_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747594","article-title":"Alternative complement pathway inhibition does not abrogate meningococcal killing by serum of vaccinated individuals","volume":"12","author":"Ispasanie","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.09.027_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732146","article-title":"Alternative complement pathway inhibition abrogates pneumococcal opsonophagocytosis in vaccine-naive, but not in vaccinated individuals","volume":"12","author":"Muri","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.09.027_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.20203110S155c","article-title":"LNP023: a novel oral complement alternative pathway factor b inhibitor safely and effectively reduces proteinuria in c3 glomerulopathy","volume":"31","author":"Wong","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2023.09.027_bib51","article-title":"FC 036IPTACOPAN (LNP023): A novel oral complement alternative pathway factor b inhibitor safely and effectively stabilises eGFR in C3 glomerulopathy","volume":"36","author":"Wong","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.09.027_bib52","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.kint.2023.09.027_bib53","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171469","volume":"140","author":"Peffault de Latour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.kint.2023.09.027_bib54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.09.027_bib55","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy\u2014an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823007548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823007548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:51:48Z","timestamp":1730422308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823007548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0085253823007548"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.09.027","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.09.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.10.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}